Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

盘后交易 10-20 17:26:00 EDT

3.19

-0.11

-3.33%

盘后3.32

+0.13+4.08%

16:35 EDT

最高3.33	最低3.12	成交量81.92万
今开3.27	昨收3.30	日振幅6.36%
总市值9,982万	流通市值5,867万	总股本3,129万
成交额263.85万	换手率4.45%	流通股本1,839万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":3.19,"timestamp":1792526400000,"preClose":3.3,"halted":0,"volume":819177,"hourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.19,"latestTime":"16:35 EDT","volume":10170,"amount":32553.735740999997,"timestamp":1792528522080,"change":0.13,"changeRate":0.040752,"amplitude":0.040752},"delay":0,"changeRate":-0.0333333333333333,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"盘后交易","change":-0.11,"latestTime":"10-20 17:26:00 EDT","open":3.27,"high":3.33,"low":3.12,"amount":2638467.5390520003,"amplitude":0.063636,"askPrice":3.31,"askSize":200,"bidPrice":3.1,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792540800000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.3,"preHourTrading":{"tag":"盘前","latestPrice":3.3,"preClose":3.3,"latestTime":"07:06 EDT","volume":115,"amount":379.340012,"timestamp":1792494378027,"change":0,"changeRate":0,"amplitude":0.042424},"postHourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.19,"latestTime":"16:35 EDT","volume":10170,"amount":32553.735740999997,"timestamp":1792528522080,"change":0.13,"changeRate":0.040752,"amplitude":0.040752},"volumeRatio":1.017416,"impliedVol":2.976,"impliedVolPercentile":0.9044},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2676630607","title":"德国默克斥13亿美元收购Silence Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2676630607","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676630607?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:13","pubTimestamp":1792458828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676516184","title":"美股异动 | 生物技术公司City Therapeutics(CTY.US)登陆美股市场 开盘后涨近24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676516184","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676516184?lang=zh_cn&edition=full","pubTime":"2026-10-17 00:00","pubTimestamp":1792166400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，City Therapeutics登陆美股市场，截至发稿，该股涨近24%，报22.315美元。City Therapeutics是一家总部位于美国马萨诸塞州剑桥市的临床阶段生物技术公司，成立于2023年，专注于开发新一代RNA干扰疗法，通过抑制与疾病相关的特定蛋白质表达，治疗具有重大未满足医疗需求的疾病。公司由RNAi领域资深专家创立，联合创始人兼执行董事长John Maraganore曾担任RNAi制药先驱Alnylam的首席执行官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CTY","BK4007","BK4139","LENZ","WDNA","BK4539","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356164","title":"杰富瑞将Spyre Therapeutics列为2027年生物科技首选股，三款炎症性肠病联合疗法将公布临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356164","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675356164?lang=zh_cn&edition=full","pubTime":"2026-10-16 15:26","pubTimestamp":1792135560,"startTime":"0","endTime":"0","summary":"10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。Spyre目前正在推进三款针对溃疡性结肠炎和克罗恩病的联合治疗方案，预计均将在2027年公布II期临床试验数据。杰富瑞认为，这些结果表明，通过联合不同炎症通路的治疗机制，可能进一步改善炎症性肠病患者的临床疗效。截至10月15日收盘，Spyre股价上涨1.87%，报80.10美元。对于未来一年，杰富瑞最关注的仍是三款炎症性肠病联合疗法的II期临床结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-16/doc-inivmazi7741271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IEIH","BK4588","GDOC","MEDX","LNGR","159837","SYNB","XBI","BK4127","BK4585","BK4139","IBBJ","BK4007","BK4559","BK4581","LENZ","AGNG","HBImain","JEF","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674850360","title":"City Therapeutics冲刺美股：拟募资1.8亿美元 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2674850360","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674850360?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:14","pubTimestamp":1791555254,"startTime":"0","endTime":"0","summary":"RNAi药物开发商City Therapeutics Inc(股票代码：“CTY”）日前更新招股书，准备2026年10月16日在美国纳斯达克上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261009/6392718082355915708199015.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261009/6392718082355915708199015.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35357/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["PPT","BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851717","title":"富达、Arch站台，RNAi新锐City Therapeutics(CTY.US)冲刺美股IPO，拟募资至多1.85亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674851717?lang=zh_cn&edition=full","pubTime":"2026-10-09 20:23","pubTimestamp":1791548622,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4139","FRHC","REDS","LENZ","KCE","BK4127","CTY","BK4539","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674830635","title":"Definium Therapeutics股价盘前上涨4%，此前摩根大通首次覆盖该股并给予增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2674830635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674830635?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:31","pubTimestamp":1791538312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["DFTX","BK4539","BK4582","LENZ","PGF","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674836788","title":"小分子生物技术公司Iambic Therapeutics(IAM.US)IPO定价15-17美元/股 拟筹资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674836788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674836788?lang=zh_cn&edition=full","pubTime":"2026-10-09 14:50","pubTimestamp":1791528639,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，依托自研人工智能平台开发小分子抗癌疗法、处于一期临床阶段的生物技术公司Iambic Therapeutics于周四公布了其IPO条款。按拟发行价区间中值计算，Iambic Therapeutics的完全摊薄市值将达到8.09亿美元。据了解，Iambic Therapeutics是一家临床阶段的生物技术公司，将专有AI模型与自动化高通量化学和生物学相结合，用于设计小分子药物。Iambic Therapeutics成立于2019年，截至2026年6月30日的过去12个月实现营收1800万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UDN","BK4539","UUP","HELX","WDNA","IAM","LENZ","BK4007","BK4139","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672786793","title":"United Therapeutics股价上涨12.2%，此前该公司赢得了针对Liquidia的法院裁决。","url":"https://stock-news.laohu8.com/highlight/detail?id=2672786793","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672786793?lang=zh_cn&edition=full","pubTime":"2026-10-01 00:32","pubTimestamp":1790785955,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671878563","title":"United Therapeutics股价上涨11%，创下自3月份以来的最大涨幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2671878563","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671878563?lang=zh_cn&edition=full","pubTime":"2026-09-30 23:28","pubTimestamp":1790782109,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221063","title":"美股异动｜Summit Therapeutics大涨超23%，获阿斯利康20亿美元投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671221063?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:58","pubTimestamp":1790690324,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671217716","title":"美股开盘，uniQure 跌 39%，Summit Therapeutics 涨 19.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671217716","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671217716?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:31","pubTimestamp":1790688703,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Gate 行情数据显示，美股开盘，道指跌 0.1%，标普 500 指数涨 0.13%，纳指涨 0.3%。生物制药公司 uniQure 跌 39%，因其亨廷顿症基因疗法的 48 个月数据未达统计显著性。Summit Therapeutics 涨 19.2%，此前阿斯利康拟向该公司投资 20 亿美元合作开发抗癌药物。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2293025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162346253","title":"美股开盘｜标普小幅高开；Summit Therapeutics涨逾20%、纳微半导体涨超12%；芯片股走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1162346253","media":"美股开盘","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162346253?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:31","pubTimestamp":1790688673,"startTime":"0","endTime":"0","summary":"热门个股方面，Summit Therapeutics涨20.16%，因获阿斯利康20亿美元投资；纳微半导体涨7.50%，获得美国陆军拨款开发碳化硅器件；三倍做多半导体ETF-Direxion Daily涨4.30%；迈威尔科技涨2.72%，受AI数据中心需求提振；英伟达涨0.88%，1500亿美元回购计划强化信心；另一方面，Fair Isaac跌19.79%，因竞争加剧打压盈利预期。Summit Therapeutics获阿斯利康20亿美元投资。双方将联合开发创新癌症疗法，巨额资金与合作前景带动Summit股价大涨逾20%。AT&T与康宁签署逾30亿美元光纤供应协议。Fair Isaac遭下调评级股价重挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","XSEM","BERZ","BK4139","ESmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671929450","title":"Summit Therapeutics美股盘前涨超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671929450","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671929450?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:01","pubTimestamp":1790668879,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265237","title":"据报道，Summit Therapeutics（SMMT）周一表示，英国制药公司阿斯利康（AstraZeneca，AZN","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671265237?lang=zh_cn&edition=full","pubTime":"2026-09-29 07:52","pubTimestamp":1790639529,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SMMT","GSKH","LU2488822045.USD","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669124044","title":"Viking Therapeutics Inc.收涨36%，创2024年2月份以来最佳单日表现。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669124044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669124044?lang=zh_cn&edition=full","pubTime":"2026-09-23 04:04","pubTimestamp":1790107466,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142648","title":"Viking Therapeutics涨超35%！减肥药传来捷报：给药频率减半仍维持97%减重","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142648","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669142648?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:50","pubTimestamp":1790085009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Viking Therapeutics周二盘前一度飙升近50%，此前这家生物科技公司宣布，其实验性肥胖症药物VK2735帮助患者在用药频率从每周一次降至每两周一次的情况下，仍维持了大部分减重成果。这一结果有望进一步增强VK2735在快速扩张的减肥药市场中的竞争地位。截至发稿，VKTX股价上涨近23%。今年以来，该股累计下跌约15%。据了解，VK2735是Viking的主要肥胖症候选药物，正在开发注射剂和口服剂两种剂型。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499522.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RSPH","PINK","VKTX","BK4588","PJP","MEDI","THNR","BK4585","BK4599","NVOX","TRUH","CURE","BK4139","IYH","LENZ","NVOC","OZEM","FHLC","BK4539","XLVI","BK4007","FXH","NBDS","NVOH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2669198183","title":"Travere Therapeutics首席执行官Eric Dube将于2026年12月卸任。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669198183","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669198183?lang=zh_cn&edition=full","pubTime":"2026-09-22 04:06","pubTimestamp":1790021208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4139","BK4007","LENZ","FFTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964804","title":"百利天恒(688506.SH)子公司拟500万美元投资创新药企业Connexus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964804","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668964804?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:44","pubTimestamp":1789645459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，为拓宽公司在除创新ADC药物研发平台，创新多特异性抗体药物研发平台，以及特异性增强双特异性抗体平台及创新ARC(核药)研发平台以外其他前沿技术赛道的布局，补充公司技术矩阵。公司全资子公司盘古资本拟以500万美元认购Connexus Therapeutics388.1万股A轮优先股股份，本次增资完成后，公司将持有Connexus 7.91%股权。Connexus是一家创新药企业，专注于肿瘤领域小分子药物的开发，其在研项目均处于临床前研发阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","IBBQ","91194","BK1574","BK4139","LENZ","MEDX","LNGR","BK0239","688506","159992","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667612838","title":"生物科技公司Electra Therapeutics(ETRA.US)IPO定价14-16美元/股 拟筹资3.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667612838","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667612838?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:18","pubTimestamp":1789456715,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发靶向SIRP抗体、用于免疫疾病和癌症治疗的II/III期的生物科技公司Electra Therapeutics周一公布了首次公开募股的发行条款。Electra Therapeutics正在开发一类精准药物，靶向特定免疫细胞群体上表达的信号调节蛋白。Electra Therapeutics欲借今年生物科技板块IPO强劲表现的东风，为其处于临床阶段的免疫介导疾病和癌症药物管线筹集资金。汇编数据显示，今年美国生物科技与制药公司的IPO累计募资额已达68亿美元，平均加权回报率接近70%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","BK4007","XBI","UUP","BK4588","BK4539","AGNG","BK4585","IBBJ","IPOS","ETRA","HBImain","GDOC","159837","IEIH","BK4581","SYNB","UDN","BK4139","LNGR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166014884","title":"新闻稿：Korsana Biosciences完成与Cyclerion Therapeutics的合并及此前公布的3.8亿美元私募融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1166014884","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166014884?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:07","pubTimestamp":1788898066,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年9月8日——致力于开发创新疗法以减轻神经退行性疾病负担的生物技术公司Korsana Biosciences, Inc.今日宣布，此前公布的与Cyclerion Therapeutics, Inc.的合并已正式完成。合并后的公司将以Korsana Biosciences, Inc.的名义运营，其股票预计于2026年9月9日开始在纳斯达克资本市场交易，代码为\"KRSA\"。根据此前披露的合并协议条款，每股Korsana普通股转换为获得约0.2074股合并公司普通股的权利，该比例已根据合并前即刻生效的Cyclerion Therapeutics普通股1比7反向股票分割进行调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4099","BK4604","BK4539","03160","LENZ","TM","BK4139","BK4588","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0859},{"period":"1month","weight":-0.1892},{"period":"3month","weight":-0.3605},{"period":"6month","weight":-0.6697},{"period":"1year","weight":-0.9137},{"period":"ytd","weight":-0.7937}],"compareEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0243},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.1537},{"period":"ytd","weight":0.124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":0.01095},{"month":9,"riseRate":0.5,"avgChangeRate":-0.02143},{"month":10,"riseRate":0.5,"avgChangeRate":-0.079726},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}